UGCG and colorectal cancer: Recent studies with oxaliplatin, the third-generation platinum drug, demonstrated that elevated GCS and GlcCer levels accompanied resistance in colorectal cancer cells, the first work to identify a role for ceramide glycosylation in oxaliplatin resistance [130].